Thus, high plasma VEGF-C at baseline may represent a predictive factor for patients with HCC treated with sunitinib, consistent with potent inhibition of VEGFR-2 and -3 by this tyrosine kinase inhibitor. The gene discussed is KDR; the disease is hepatocellular carcinoma.